– Data from University Hospital Basel (UHB) study supports the clinical development of MindMed’s proprietary MM-120 product candidate for Generalized Anxiety Disorder (“GAD”) – – Patient dosing in Phase 2b trial ongoing for MM-120 in GAD– – MindMed currently owns and retains all clinical data and manufacturing rights for MM-120 and intends to continue broadening its intellectual property portfolio…


Previous articleSmall Pharma to Participate in Upcoming September Investor Conferences
Next articleBexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit